Revenues from 14.7 to 15 Mio. EUR, net profit from - 2.3 to about + 3 Mio. EUR

Kleinostheim, February 25, 2004 - curasan AG (WKN 549 453) today announced its preliminary results for the financial year ended December 31, 2003. Management anticipates total revenues of EUR 15 million for the period (2002: EUR 14.7 million) The net profit is expected to be in the range of EUR 3 million (2002: net loss of EUR 2.3 million).

The above-par result was achieved through the sale of curasan's Pharmaceuticals unit. Excluding this disposal, the Company would have achieved its revenue target of approx. EUR 17.5 million.

Anticipating an increase from EUR 6 million to approx. EUR 10 million, the Management Board has forecast considerable growth potential for the current financial year as a result of its decision to focus on regenerative medicine and the measures already implemented in this area over the past years. In addition, the recently announced product launches and distribution agreements are expected to contribute to the Company's revenue target of EUR 10 million, with more or less break-even results.

The definitive financial results will be announced on March 24, 2004.